港股異動 | 昭衍新藥(6172.HK)一度漲超4% 機構指業績增長有望持續
格隆匯1月25日丨昭衍新藥(6172.HK)盤中漲超4%,現報63.75港元,總市值243億港元。昭衍新藥A股亦漲約1%。日前公司預計2021年歸母淨利潤5.43-5.74億元,同比增長72.3%-82.3%;Q4單季度歸母淨利潤2.95-3.26億元,同比增長72.5%-90.6%。國泰君安預計Q4季度在手訂單高效執行,貢獻業績超預期增長,且業績增長有望持續,維持增持評級。據悉,2021年昭衍(蘇州)啟動約7500平米動物房裝修工程,2022年下半年有望投產,充足產能供應為業績增長提供保障。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.